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Abstract
Background: Infections with hepatitis C virus (HCV) progress to chronic phase in 80% of patients. To date, the
effect produced by HCV on the expression of microRNAs (miRs) involved in the interferon-b (IFN-b) antiviral
pathway has not been explored in details. Thus, we compared the expression profile of 24 selected miRs in IFN-b-
treated Huh-7 cells and in three different clones of Huh-7 cells carrying a self-replicating HCV RNA which express
all viral proteins (HCV replicon system).
Methods: The expression profile of 24 selected miRs in IFN-b-treated Huh-7 cells and in HCV replicon 21-5 clone
with respect to Huh-7 parental cells was analysed by real-time PCR. To exclude clone specific variations, the level of
16 out of 24 miRs, found to be modulated in 21-5 clone, was evaluated in two other HCV replicon clones, 22-6 and
21-7. Prediction of target genes of 3 miRs, confirmed in all HCV clones, was performed by means of miRGator
program. The gene dataset obtained from microarray analysis of HCV clones was farther used to validate target
prediction.
Results: The expression profile revealed that 16 out of 24 miRs were modulated in HCV replicon clone 21-5.
Analysis in HCV replicon clones 22-6 and 21-7 indicated that 3 out of 16 miRs, (miR-128a, miR-196a and miR-142-
3p) were modulated in a concerted fashion in all three HCV clones. Microarray analysis revealed that 37 out of
1981 genes, predicted targets of the 3 miRs, showed an inverse expression relationship with the corresponding
miR in HCV clones, as expected for true targets. Classification of the 37 genes by Panther System indicated that the
dataset contains genes involved in biological processes that sustain HCV replication and/or in pathways potentially
implicated in the control of antiviral response by HCV infection.
Conclusions: The present findings reveal that 3 IFN-b-regulated miRs and 37 genes, which are likely their
functional targets, were commonly modulated by HCV in three replicon clones. The future use of miR inhibitors or
mimics and/or siRNAs might be useful for the development of diagnostic and therapeutic strategies aimed at the
recovering of protective innate responses in HCV infections.
Background
Infection with hepatitis C virus (HCV) represents the
major cause of liver disease, affecting more than 170 mil-
lion individuals worldwide. After a sub-clinical phase,
greater than 80% of patients progress to persistent HCV
infection, the leading cause of chronic liver disease asso-
ciated with cirrhosis and hepatocellular carcinoma [1,2].
In the last years, microarray technology provided a com-
prehensive analysis of alterations in gene expression
induced by HCV and revealed important processes of
virus-host interactions [3-7]. Interestingly, microarray stu-
dies indicated that HCV stimulates the endogenous Type I
Interferon (IFN-a/b) pathway as suggested by activation of
IFN-stimulated genes (ISGs) [8-15]. Recently, it has been
proposed that also microRNAs (miRs), a class of small
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any medium, provided the original work is properly cited.non-coding regulatory RNAs, are involved in the antiviral
pathway induced by IFN-b treatment. The synthetic intro-
duction of five IFN-b-induced miRs into HCV replicon
cells may simulate the antiviral effect of IFN-b blocking
HCV replication and infection. These five miRs (miR-196,
miR-296, miR-351, miR-431 and miR-448) likely induced
an antiviral state either through alteration of gene expres-
sion and/or directly targeting HCV RNA, as was demon-
strated for two of them (miR-196 and miR-448) [16].
Although HCV activates the endogenous IFN-a/b
pathway it conversely shows an impressive ability to
induce persistent infections. Indeed, it is also clear that
HCV has evolved several mechanisms to control the
IFN antiviral response, inhibiting the pathway at differ-
ent levels [17]. Recently, it has been suggested that an
improper pre-activation of ISGs in the liver of HCV
infected patients may hinder the antiviral response. The
d i s c o v e r yo fag e n e t i cp o l y m orphism in the interleukin
28B (IL28B) region on chromosome 19 of HCV patients
depicted a more complex virus-host interaction. The
IL28B non-CC variant has been associated with non-
response to the IFN therapy and with lower rates of
spontaneous clearance of HCV infection. The poor-
response variant is also associated with higher intrahe-
patic expression level of ISGs [18-20].
A missing aspect in this scenario is the study of the
effect produced by HCV on the expression of IFN-b-
induced miRs. This is a relevant issue to understand how
the virus can suppress the innate antiviral signaling and
induce a persistent infection.
In a previous paper, we identified a common transcrip-
tional response of Huh-7 cells to different clones of full-
length HCV replicon [21]. Although a more advanced
HCV cell culture models that release HCV viral particles
has been developed [22-24], the replicon system has the
advantage of taking into account the cellular gene expres-
sion variability of different HCV replicon cell clones. This
approach allows searching for modulated genes shared by
all clones, which are likely to be strictly needed for viral
replication in different cellular contexts.
On this basis, we used the replicon system to identify
IFN-regulated miRs that are modulated by HCV RNA
replication. In particular, we analyzed the expression
profile of 24 selected miRs in IFN-b-treated Huh-7 cell
line and in three cell clones carrying a full-length HCV
replicon (clones 21-5, 22-6 and 21-7). Among the identi-
fied 16 miRs modulated in the 21-5 clone, 3 miRs
showed concordant expression when analyzed in the
two other HCV replicons. By a combined approach,
based on bioinformatic prediction and microarray analy-
sis, we also identified 37 genes, targeted by the 3 miRs,
which are involved in pathways and biological processes
potentially implicated in the control of antiviral response
by HCV infection.
Results
Expression of IFN-b-regulated miRs in 21-5 HCV replicon
cells and in IFN-b-treated Huh-7 cells
To determine the impact of HCV RNA replication and
protein synthesis on IFN-b-regulated miRs, we com-
pared the expression profile of selected miRs in 21-5
cells, harbouring a full-length HCV genome, and in
IFN-b-treated Huh-7 cells with the Huh-7 parental cell
line.
In particular, the list of assayed miRs includes (a) eight
IFN-b-induced miRs, which displayed complementarity
in their seed sequences with HCV RNA genome (miR-1,
miR-30, miR-128, miR-196, miR-296, miR-351, miR-431,
miR-448) [16], (b) two miRs reported as IFN-b-unre-
sponsive miRs (miR-125 and miR-142) [16], (c) miR-122a
that promotes HCV RNA replication [25] and (d) three
miRs (miR-155, miR-146a and miR-146b) modulated in
innate immune response in monocytes/macrophages
[26,27]. Actually, the name of five of the above miRs
(miR-30, miR-128, miR-196, miR-125 and miR-142) indi-
cates miR families, not just individual mature miR spe-
cies: thus, we analysed the level of each member of those
families. Overall, the expression profile of 24 miRs in 21-
5 and IFN-b-treated Huh-7 cell lines was analysed (Table
1). Three miRs (miR-351, miR-431 and miR-448) showed
an expression level below the detection limit of the assay
(Ct ≥40), while five miRs were not differentially expressed
in 21-5 cells (miR-125b, miR-30e-5p, miR-30e-3p, miR-
30a-5p, miR-30d: fold-change values < 1.2 or > -1.2 in
21-5 cells). These eight miRs were not evaluated further.
The expression profile of the remaining 16 miRs
revealed that they were modulated by IFN-b and/or HCV
(Figure 1). In particular, concordant modulation (up- or
down-regulation) of 9 miRs (miR-1, miR-30a-3p, miR-
142-5p, miR-142-3p, miR-146a, miR-146b, miR-155,
miR-128a and miR-296) was observed in IFN-b-treated
Huh-7 cells and in 21-5 replicon cells (Figure 1, panel A).
This result indicates that HCV replication can induce a
miR signature as IFN-b treatment. Five miRs were modu-
lated in 21-5 replicon cells only, as the level in IFN-b-
treated Huh-7 cells was within the ± 1.2 range set as
background (Figure 1, panel B: miR-196b, miR-125a,
miR-122a, miR-30c and miR-30b). Two miRs were
modulated in an opposite manner in IFN-b-treated Huh-
7 cells and in 21-5 replicon cells (Figure 1, panel C: miR-
128b and miR-196a).
Identification of common miRs modulated in different
HCV replicon clones
To exclude that the miR expression profile was peculiar
of the 21-5 clone, we analyzed the expression level of the
16 miRs in two other HCV replicon clones, 22-6 and 21-
7. The analysis revealed that 3 miRs showed concordant
modulation in HCV clones as compared to Huh-7 cells
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down-regulated while miR-142-3p was up-regulated in
all HCV clones.
Identification of candidate miR target genes
To predict target genes, which may be co-regulated by the
3 concordant miRs, we used miRGator, an on-line inter-
face that uses multiple target prediction programs. It has
been shown that, to date, no program is able to predict all
experimentally confirmed target genes. Thus, to avoid as
much as possible loss of putative target genes, relaxed
options were used in miRGator [target genes predicted by
at least one of the following programs: TargetScanS, miR-
anda and PicTar (4-way)]. After removal of multiple
mRNAs corresponding to alternative mRNA transcripts
from a single gene, individual gene lists were merged and
a final list of 1981 total target genes was obtained, includ-
ing genes controlled by at least one of the three miRs.
Identification of genes common to miR target list and
HCV microarray dataset
The observation of an inverse relationship between
levels of miRs and levels of their target mRNAs, due to
mRNA degradation of target genes, provides opportu-
nities for validation of predicted targets using microar-
ray profiling [28]. On this basis, to determine the
candidate target genes directly regulated by miR-128a,
miR-196a and miR-142-3p, we overlapped two datasets:
the list of 1981 total target genes predicted for the 3
miRs (dataset 1) and a microarray dataset including 676
genes (725 probes) modulated in all HCV clones as
compared to Huh-7 cells (dataset 2) reported in our
previous study [21]. As shown in Figure 3, 83 genes
were common to both datasets indicating that target
genes of the 3 miRs account for 12, 3% (83 out of 676)
of the differentially expressed genes detected in all three
HCV clones. The list of 83 genes, including relevant
informations, is provided in Additional file 1, Table S1.
As levels of most miRs and their target mRNAs exhibit
an inverse expression relationship, we used gene expres-
sion profiling data to identify functional targets and vali-
date target prediction, as previously reported [29]. By
using this approach we found that 37 out of 83 (44, 5%)
of the predicted target genes showed an expression level
inversely correlated with that of the corresponding miR
suggesting that, at least for these genes, a direct connec-
tion to miR regulation may be suggested. A complete
list of the 37 genes (22 up-regulated and 15 down-regu-
lated) and the corresponding 3 miRs is provided in
Table 2. The list includes symbol, name, probe ID, fold-
change (FC) and p-value of the genes all obtained from
microarray dataset. In addition, a functional description
of the genes by Panther Protein Classification System is
enclosed [30]. Overlapping the 37 genes with the dataset
of genes resulting from microarray analysis of Huh-7.5
cells infected with HCV genotype 2a chimeric virus J6/
JFH [31] revealed 4 common genes (RND3, LTB4DH,
RIOK3 and CHAF1B) which showed the same direction
of regulation (i.e. up-regulated or down-regulated genes)
in both HCV clones and J6/JFH microarray datasets
supporting the biological relevance of these genes in
HCV replicative cycle. Finally, to explore the involve-
ment of the identified genes in HCV response to endo-
genous IFN, we also overlapped the list of 37 genes with
the dataset of 1996 human genes annotated in the
INTERFEROME database [32]. As shown in Table 2,
four genes (HNMT, XPO1, PMPCB and HMGB1) were
identified as Interferon Regulated Genes (IRGs).
Biological functions of the miR target genes
To classify genes into biological categories, we analyzed
the Gene Ontology annotations of the 37 common genes
with the Panther Protein Classification System [30]. As
shown in Table 3, Panther System found several func-
tional categories that were significantly enriched in this
gene set compared to the entire NCBI reference list of
human genome. We considered, as potentially
Table 1 Fold-change of 24 selected miRs in IFNb-treated
Huh-7 and 21-5 cell lines vs. Huh-7
Huh-7+ IFNb 21-5
miR-1 30, 13 22, 11
miR-30a-3p 4, 46 8, 79
miR-146a 1, 54 2, 73
miR-142-5p 2, 83 2, 20
miR-146b 2, 09 2, 11
miR-142-3p 2, 09 1, 74
miR-296 -1, 47 -1, 40
miR-155 -1, 69 -1, 61
miR-128a -1, 47 -1, 88
miR-128b -3, 30 2, 09
miR-196a 1, 31 -1, 50
miR-125a 1, 05 3, 43
miR-196b 1, 11 2, 92
miR-30c -1, 12 1, 30
miR-30b -1, 04 1, 28
miR-122a 1, 14 -1, 63
miR-125b -1, 10 1, 19
miR-30e-5p 1, 14 1, 18
miR-30e-3p -2, 12 1, 17
miR-30a-5p -1, 38 1, 15
miR-30d -1, 12 1, 02
miR-351 n.d. n.d.
miR-431 n.d. n.d.
miR-448 n.d. n.d.
In bold: fold-change values > 1.2 or < -1.2
n.d.: not detected, i.e. miRs showing an expression level below the detection
limit of the assay (Ct ≥ 40)
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determined by the binomial statistic [33]. The 37 genes
of the dataset were significantly classified by the Panther
system in 6 biological processes (i.e., processes in which
genes participate) and 3 molecular functions (i.e., biologi-
cal functions of gene products). Compared with the
NCBI reference list of human genome, this dataset
showed a larger proportion of genes encoding proteins
involved in chromatin binding and architecture, organelle
organization, intracellular transport and neurotransmitter
secretion (Table 3). In addition, genes associated with
catalytic activity, enzyme regulator activity and chromatin
binding were represented much more abundantly in the
dataset. Interestingly, genes involved in the Ubiquitin
proteasome pathway were also present in the dataset
(Table 3). Additional file 2, Table S2 reports the complete
list of the genes that are responsible for statistical enrich-
ment of each category shown in Table 3
Discussion
In the present study we analyzed the effect of HCV
replication on the expression of selected miRs involved
in the IFN-pathway. In particular, we identified 3 miRs
that are equally modulated by HCV in three HCV repli-
con clones and by IFN treatment. Moreover, we also
identified 37 out of 83 predicted target genes, differen-
tially expressed in HCV replicon cells, which are most
likely functional targets of these 3 miRs: in fact they
showed an inverse expression relationship with the level
of the 3 miRs, as described for true targets. These genes
could be implicated in regulation of the host response
to HCV.
About one half predicted targets did not show the
expected inverse expression relationship with miR level,
but this result is not surprising. First, computational
prediction by miRgator was based on predictions from
the widely used programs miRanda, TargetScanS and
Figure 1 Fold-change of 16 miRs modulated in IFN-b-treated Huh-7 cells and in 21-5 replicon cells. Total RNA from both cell lines was
used to assess miR levels using real time RT-PCR. miR levels from Huh-7 cells were set as the basis for the comparative results. miRs with a fold-
change > 1.2 or < -1.2 were considered differentially expressed in 21-5 vs. Huh-7 cells. The mean of three independent biological replicas ± SD
is reported; the RNA extract from each biological replica had been assayed by real-time RT-PCR in triplicate (three technical replicas per each
RNA extract). (A) Concordant modulation (up- or down-regulation) of 9 miRs (miR-1, miR-30a-3p, miR-142-5p, miR-142-3p, miR-146a, miR-146b,
miR-155, miR-128a and miR-296) in IFN-b-treated Huh-7 cells and in 21-5 replicon cells. (B) Modulation of five miRs (miR-196b, miR-125a, miR-
122a, miR-30c and miR-30b) in 21-5 replicon cells. (C) Discordant modulation of two miRs (miR-128b and miR-196a) in IFN-b-treated Huh-7 cells
and in 21-5 replicon cells.
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grams, as well as any other available prediction program,
still have a very high false-positive rate, estimated to be
up to 40% [34,35]: i.e. up to 40% genes predicted to be
targeted by a miR are not, actually, true targets, and
they will not show any inverse relationship. Second,
each mRNA is usually targeted by multiple miRs and, in
addition, each mRNA has its own set of modulating
miRs. Whether or not a change in the level of a single
miR can prevail on the effect of the other miRs simulta-
neously targeting the same mRNA in physiological con-
ditions is, at present, poorly understood. However, it is
p o s s i b l ei ns o m ec a s e si tw i l lp r o d u c en oe f f e c ta n d ,
thus, even a true target will not show the expected
inverse relationship.
The recent discovery of the roles of miRs in many
human diseases suggests that studies exploring the rela-
tionship between HCV and miRs/mRNA may provide
new insights into host cell response to HCV infection.
Importantly, this approach also gives the opportunity to
identify viral mechanisms that control the antiviral
defense. Recently, it has been demonstrated that five
IFN-b-modulated miRs (miR-196, miR-296, miR-351,
miR-431 and miR-448) showed significant effect on HCV
replication and at least two of them (miR-196 and miR-
448) are directly targeting the HCV genomic RNA [16].
Moreover, it seems that level of miR-122 is inversely cor-
related with the antiviral defense [16,36,37].
Our expression analysis revealed that miR-196a was
down-regulated in all three HCV replicon clones. Thus,
at least for this component of the pathway, it seems that
modulation of IFN-miRs may be altered by HCV in repli-
con cells. Interestingly, this miR targets the HCV RNA
[16], thus, down-regulation of miR-196a may indirectly
influence viral replication also by up-regulation of speci-
fic target genes. Accordingly, 11 genes, controlled by
miR-196a, showed by microarray analysis an inverse
expression relationship suggesting that they can be likely
considered functional targets of miR-196a. Moreover,
gene ontology analysis of the 11 genes highlights that
some of them are really involved in pathways such as,
extracellular matrix constitution (LAM4), oxidative stress
(HADH2, LTB4DH) and cytoskeletal network (CENPE),
which are relevant for HCV RNA replication [7,38,39].
As for the IFN-b-regulated miR-296, miR-351, miR-
431, miR-448 and miR-122 (16) our data indicate that
their expression in different HCV replicon clones is
either not concordant (miR-296, and miR-122a) or not
detected (miR-351, miR-431 and miR-448). In particular,
miR-122a was down-regulated in 21-5 and 21-7 clones
but its level was not modified in clone 22-6 (data not
shown) while miR-296 was down-regulated in 21-5 clone
and up-regulated in clone 22-6 and 21-7, respectively
(data not shown). Moreover, miR 351, miR-431 and miR-
448 were not detected in all clones examined supporting,
at least for miR-448, what found in human biopsies
where miR-448 is totally absent [37].
Interestingly, we observed that two miRs, miR-142-3p
and miR-128a, were up-regulated and down-regulated
respectively by IFN-b treatment of Huh-7 cells and in
HCV replicon-expressing cells. Although modulation of
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Figure 2 Concordant expression of 3 miRs in different HCV
replicon clones. Total RNA from 21-5, 21-7 and 22-6 replicon cell
lines was used to assess the level of miR-128a, miR-196a and miR-
143-3p, using real time RT-PCR. miR levels from Huh-7 cells were set
as the basis for the comparative results. The mean of three
independent experiments ± SD is reported.
1898       83         593
dataset 1
(list of predicted miR targets)
1981 genes
dataset 2
(HCV replicon clones vs. Huh-7)
676 genes
37
(44,5%)
target genes whose expression is 
inversely correlated with miR expression
Figure 3 Venn diagram showing validation of predicted target
genes by microarray analysis. Dataset 1 corresponds to the list of
1981 total target genes predicted for miR-128a, miR-196a and miR-
142-3p; dataset 2 includes 676 genes differentially expressed in
microarray analysis in all HCV clones as compared to Huh-7 cells.
The number of predicted target genes differentially expressed in
microarray analysis was 83, and 37 (44, 5%) showed an expression
level inversely correlated with that of the corresponding miR.
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Page 5 of 11Table 2 Reverse regulatory association of 3 differentially expressed miRNAs and their 37 predicted target genes in HCV replicon clones vs. Huh-7
Gene_Symbol Gene_name ProbeID Fold-
change
p-
value
Biological process and Molecular function
Down-regulated
miR
miR-128a CAMTA1 calmodulin binding transcription activator 1 164871 1.426 0.045 Signal transduction/Calcium mediated signaling
miR-128a CAST calpastatin 222724 1.788 0.002 Cysteine protease inhibitor|Select regulatory molecule
miR-128a CORO1C coronin, actin binding protein, 1C 107201 1.402 0.027 Cytoskeletal protein|Actin binding cytoskeletal protein
miR-128a PARK7 Parkinson disease (autosomal recessive, early onset) 7 136848 1.529 0.003 Nucleic acid binding
miR-128a REPS1 RALBP1 associated Eps domain containing 1 147893 1.352 0.002 Intracellular protein traffic/Endocytosis
miR-128a RND3
# Rho family GTPase 3 129829 2.161 0.041 G-protein|Small GTPase|Select regulatory molecule
miR-128a SAA4 serum amyloid A4, constitutive 214434 1.880 0.029 Apolipoprotein;Defense/immunity protein
miR-128a TMCC1 transmembrane and coiled-coil domain family 1 112169 1.369 0.031 unclassified
miR-128a TRAPPC4 trafficking protein particle complex 4 205369 1.502 0.012 Membrane traffic protein
miR-128a UBE2E3 ubiquitin-conjugating enzyme E2E 3 (UBC4/5 homolog,
yeast)
201108 1.505 0.030 Ligase|Other ligase
miR-128a VAMP8 vesicle-associated membrane protein 8 (endobrevin) 226943 2.586 0.011 SNARE protein|Membrane traffic protein
miR-196a ARMET arginine-rich, mutated in early stage tumors 144765 1.816 0.029 unclassified
miR-196a HADH2 hydroxyacyl-Coenzyme A dehydrogenase, type II 142475 1.421 0.031 Oxidoreductase|Reductase|Dehydrogenase;Oxidoreductase
miR-196a HIST1H2BD histone 1, H2bd 148940 2.656 0.020 DNA binding
miR-196a HNMT
▲ histamine N-methyltransferase 227509 1.423 0.039 unclassified|IRG
▲
miR-196a LAMA4 laminin, alpha 4 101059 2.660 0.033 Extracellular matrix|Extracellular matrix linker protein
miR-196a LTB4DH
# leukotriene B4 12-hydroxydehydrogenase 210882 1.961 0.001 Oxidoreductase|Reductase|Dehydrogenase;Oxidoreductase
miR-196a PI3 peptidase inhibitor 3, skin-derived (SKALP) 128827 2.558 0.018 Proteolysis|Protein metabolism and modification
miR-196a RIOK3
# RIO kinase 3 (yeast) 142169 3.226 0.018 Protein metabolism and modification|Protein
phosphorylation
miR-196a RRAGA Ras-related GTP binding A 105497 1.243 0.023 G-protein|Small GTPase|Select regulatory molecule
miR-196a ZMYND11 zinc finger, MYND domain containing 11 161540 1.665 0.036 Transcription factor|Transcription cofactor
miR-128a/miR-196a CENPE
§ centromere protein E, 312kDa 165425 1.436 0.018 Structural constituent of cytoskeleton
Up-regulated miR
miR-142-3p ZCCHC14 zinc finger, CCHC domain containing 14 200292 0.759 0.035 unclassified
miR-142-3p XPO1
▲ exportin 1 (CRM1 homolog, yeast) 105030 0.748 0.002 Intracellular protein transport|IRG
▲
miR-142-3p ATAD2 ATPase family, AAA domain containing 2 114584 0.745 0.007 Hydrolase activity
miR-142-3p TRIM33 tripartite motif-containing 33 134526 0.714 0.004 Transcription cofactor;Nucleic acid binding|Transcription
factor
miR-142-3p RAB1A RAB1A, member RAS oncogene family 122650 0.704 0.045 G-protein|Small GTPase|Select regulatory molecule
miR-142-3p TFG TRK-fused gene 210281 0.686 0.026 unclassified
miR-142-3p PMPCB
▲ peptidase (mitochondrial processing) beta 210046 0.684 0.015 Oxidoreductase activity|IRG
▲
miR-142-3p ZNF226 zinc finger protein 226 178824 0.682 0.043 Zinc finger transcription factor
miR-142-3p ANKHD1 ankyrin repeat and KH domain containing 1 224628 0.658 0.006 unclassified
miR-142-3p CXADR coxsackie virus and adenovirus receptor 108284 0.620 0.025 Other receptor|Receptor
B
r
u
n
i
e
t
a
l
.
B
M
C
G
e
n
o
m
i
c
s
2
0
1
1
,
1
2
:
4
8
5
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
1
6
4
/
1
2
/
4
8
5
P
a
g
e
6
o
f
1
1Table 2 Reverse regulatory association of 3 differentially expressed miRNAs and their 37 predicted target genes in HCV replicon clones vs. Huh-7 (Continued)
miR-142-3p CHAF1B
# chromatin assembly factor 1, subunit B (p60) 174351 0.586 0.017 Nucleic acid binding|Chromatin/chromatin-binding protein
miR-142-3p HMGB1
▲ high-mobility group box 1 151074 0.586 0.011 Proinflammatory cytokine|IRG
▲
miR-142-3p BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 109165 0.551 0.000 unclassified
miR-142-3p COG4 component of oligomeric golgi complex 4 151150 0.394 0.042 Other RNA-binding protein|Nucleic acid binding
miR-142-3p USH1C Usher syndrome 1C (autosomal recessive, severe) 195953 0.367 0.016 Cytoskeletal protein
§ Gene targeted by two down-regulated miRs
▲ Interferon regulated gene (IRG) according to the INTERFEROME database
# Gene showing same direction of regulation (up or down) in microarray analysis of HCV genotype 2a chimeric virus J6/JFH infection
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1these 2 miRs by IFN-b has never been described before,
it is consistently observed in all clones suggesting that it
may be part of the endogenous IFN response to HCV.
The IFN pathway is a highly regulated process and sev-
eral controls has been evolved to activate and turn off
this pathway. In this scenario, the temporal modulation
of specific miRs seems to represent one of the control
elements [40]. It is important to note that this process
cannot properly occur in cells sustaining HCV replica-
tion. In this case a chronic up or down-regulation of
IFN-miRs, likely induced by the virus, may negatively
affect the control of the pathway finally improving the
efficacy of the antiviral effectors. It would be interesting
to investigate whether the experimental use of miR inhi-
bitors (for miR-142-3p) or miR mimics (for miR-128a)
could influence the control of the endogenous IFN
system.
Among the 37 predicted target genes showing an
inverse expression relationship with the 3 miRs, four
genes were identified as Interferon Regulated Genes
(IRGs) according to the INTERFEROME database [32].
One of these genes (HNMT) is a predicted target gene of
miR-196a while the other three (XPO1, PMPCB and
HMGB1) are all targeted by miR-142-3p. Importantly, in
autoimmune diseases the high mobility group box 1
(HMGB1) protein was identified as a component of
immune complex-containing DNA or RNA, which may
act as endogenous IFN-b inducer [41]. Down-regulation
of HMGB1 gene (fold change 0, 58; p-value 0, 01) in all
HCV replicon clones suggests that it might contribute to
impair the activation of the IFN signaling. Currently, the
role of these four IRGs in the IFN response to HCV repli-
cation is unknown. Thus, unraveling their contribution to
the regulation of the IFN response may reveal new
mechanisms of viral persistence.
Gene Ontology annotations of the 37 common genes
also revealed the presence of two genes, UBE2E3 and
ATAD2 targets of miR-128a and miR-142-3p respectively,
which are involved in the Ubiquitin proteasome pathway.
The contribution of this pathway to HCV subversion of
the IFN response has never been investigated. This is a
quite interesting issue as several viruses use the ubiquitin
proteasome system to destabilize proteins, such as IRF3
and STAT proteins, that are important for transcription of
Interferon and Interferon-stimulated genes [42].
In attempt to validate our data, we found that 4 out of
37 genes, targeted by the 3 miRs, were also modulated,
in a concerted fashion, in HCV genotype 2a chimeric
virus J6/JFH microarray datasets [31] supporting the
biological relevance of our results. In addition, 6 genes
Table 3 Panther classification of Biological processes, Molecular functions and Pathways significantly enriched in the
set of 37 genes
Observed Genes
￿ Expected Genes
￿￿ p-value
￿￿￿
BIOLOGICAL PROCESS
Cellular process
Establishment or maintenance of chromatin architecture 4 0.55 2.12E-03
Cellular component organization
Organelle organization 4 0.59 2.85E-03
Transport
Intracellular protein transport 9 2.98 2.16E-03
Vesicle-mediated transport 7 2.10 4.26E-03
Endocytosis 4 1.04 1.96E-02
System process
Neurotransmitter secretion 3 0.63 2.45E-02
MOLECULAR FUNCTION
Catalytic activity
GTPase activity 3 0.52 1.53E-02
Enzyme regulator activity
Peptidase inhibitor activity 2 0.32 4.08E-02
Binding
Chromatin binding 2 0.34 4.59E-02
PATHWAYS
Ubiquitin proteasome pathway 2 0.13 7.19E-03
￿ Number of genes, in the dataset of 37, that map to the indicated Panther classification categories
￿￿ Expected number of genes, in the dataset of 37, based on the NCBI reference list of human genome
￿￿￿ p-value as determined by the binomial statistic. A cutoff of 0.05 has been applied
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Page 8 of 11(4 up-regulated: CEACAM1, DDIT3, SCARB2,
ZFAND2A; and 2 down-regulated: C9orf19 and RPL5)
selected from the HCV clones microarray dataset were
found to be modulated in a same way in liver biopsies
of patients showing non-CC IL28B polymorphism [20].
This polymorphism is not a good predictor of response
to IFN therapy and it is also associated with higher level
of ISG expression in the liver and propension to chroni-
city. So, it can be speculated that modulation of IFN sig-
nature as mediated by common miRs in replicon cells,
can mirror de-regulation of the IFN signaling proposed
for such patients.
Conclusions
I nt h ep r e s e n ts t u d yw eu s e dt h eH C Vr e p l i c o ns y s t e m
to identify IFN-regulated miRs that are modulated by
HCV RNA replication. By a combined approach, based
on Real-Time PCR, bioinformatic prediction and micro-
array analysis, we identified 3 IFN-b-regulated miRs and
37 genes, which are likely their functional targets, com-
monly modulated by HCV in three replicon clones.
Gene ontology classified the 37 genes into functional
categories potentially implicated in the control of anti-
v i r a lr e s p o n s eb yH C Vi n f e c t i o n .T h ef u t u r ed e s i g no f
siRNAs directed against some of these genes and the
use of miRs and antimiRs may provide an experimental
background for the development of therapeutic strate-
gies aimed at the recovering of protective innate
responses in HCV infections.
Methods
Cell lines
The Huh-7 cells carrying the Sfl HCV full-length repli-
con (genotype 1b) were obtained from Dr. R. Bartens-
chlager. The 21-5, 21-7 and 22-6 clones are cell lines
that stably replicates the HCV replicon and were pas-
saged as described [43-45]. HCV replicon cells were cul-
tured in complete DMEM supplemented with 10% FCS,
antibiotics, 1× non-essential amino acids, and 250 μg/ml
(21-5, 21-7) and 500 μg/ml (22-6) G418. Huh-7 cells
were stimulated with 100 UI/ml IFN-b for 16 h.
Quantitation of miRNAs
Total RNA was extracted from 1 × 10
6 cells using miR-
Neasy mini kit (QIAGEN) according to manufacturer’s
instructions and quantified by Bioanalyzer 2100 (Agilent
Technologies). TaqMan
® MicroRNA Assays were used
to quantitate miRs according to manifacturer’si n s t r u c -
tions (Applied Biosystems, Foster City, CA). A single
TaqMan MicroRNA assay is used for each miR. All
necessary primers and TaqMan probes are provided by
the manufacturer with each assay, but details about
sequence of primers and probes are not available
(patented). Each TaqMan MicroRNA assay includes: (a)
a “looped” primer, specific for each miR, for the reverse
transcription step (carried out with the TaqMan
®
MicroRNA Reverse Transcription Kit) and (b) a pair of
“conventional” primers for amplification as well as a
fluorescently labeled TaqMan probe for detection for
the Real-Time amplification step (carried out with the
TaqMan Universal PCR Master Mix).
In brief, 5 ng total RNA was reverse transcribed in 7.5 μl
reaction volume containing 50 nM looped miR-specific
primer, 1× RT buffer, 0.25 mM each dNTPs, 3.33 U/μl
MultiScribe™ reverse transcriptase and 0.25 U/μl RNAse
inhibitor. The reactions were incubated in an ABI Prism
7000 Sequence Detection System (Applied Biosystems) in
a 96-well plate for 30 min at 16°C, 30 min at 42°C, fol-
l o w e db y5m i na t8 5 ° C ,a n dt h e nh e l da t4 ° C .R e v e r s e
transcription products were diluted three times with
nuclease-free water prior to setting up PCR reactions.
Each microRNA Real-Time PCR (10 μl volume) was car-
ried out in triplicate, and each 10 μl reaction mixture
included 2 μl of diluted reverse transcription reaction pro-
duct, 5 μl of 2X TaqMan
® Universal PCR Master Mix, 1X
assay mix (including TaqMan
® probe and forward and
reverse primers). The reactions were incubated in an ABI
Prism 7000 Sequence Detection System (Applied Biosys-
tems) in 96-well plates at 95°C for 10 min, followed by 40
cycles of 95°C for 15 sec and 60°C for 1 min. Fold induc-
tion was calculated by 2
-ΔCt method [46] using the level of
Huh-7 cell line as a calibrator.
Prediction of genes targeted by modulated miRs
Putative gene targets of miRs found to be modulated in
HCV clones were predicted by means of the miRGator
program (available at http://genome.ewha.ac.kr/miRGa-
tor/miRNAexpression.html) that allows to combine gene
predictions by TargetScanS, miRanda and PicTar soft-
wares. To avoid loss of potential targets, a relaxed
option was selected (retrieval of genes predicted by at
least one program), so as to obtain for each miR a gene
list as wide as possible.
Gene network pathway analysis
Gene Ontology (GO) annotations were analyzed with
the Panther Protein Classification System [30] to identify
functional annotations that were significantly enriched
in this gene set compared to the entire human genome.
Gene lists modulated by HCV were mapped onto biolo-
gical pathways that were significantly represented.
Additional material
Additional file 1: Table S1. List of 83 genes resulting from overlapping
(a) predicted target genes of miR-128a or miR-196a or miR-143-3p and
(b) genes experimentally showing an expression change in HCV replicon
clones vs. parental Hu-h7 cells by microarray analysis [21].
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Page 9 of 11Additional file 2: Table S2. Individual genes in each of the classification
groups found to be significantly enriched in the set of 37 genes by
Panther.
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